MariMed Inc. Enters Exclusive Nevada Cannabis Production and Distribution Licensing Agreement
NEWTON, Mass. and LAS VEGAS, Nov. 06, 2017 (GLOBE NEWSWIRE) -- MariMed Inc., (OTCQB:MRMD) and its MariMed Advisors subsidiary today announced they have entered into an exclusive licensing agreement for Alternative Medicine Association (AMA”) to produce and distribute, in Nevada, MariMed’s branded cannabis products, including unique Kalm Fusion™ THC and CBD formulations for sublingual Mari-Melts, Kalm Chewable Tablets, Kalm Corn Popcorn, Kalm Powdered Tincture and Betty’s Eddies™ line of Fruit Chews and Berry Bombs. The companies plan to commence production in the fourth quarter of 2017.
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/21ad8601-641a-42b5-bcd6-088397cefe9b
MariMed’s Kalm Fusion and Betty’s Eddies branded lines of cannabis-infused products are all natural and precisely dosed for consistent results. AMA, will produce these and other MariMed products using MariMed’s proprietary formulations and processes and distribute them to state licensed cannabis dispensaries in Nevada.
“MariMed licenses its products to state-licensed facilities and operators, such as AMA, who meet MariMed’s strict production standards and will apply MariMed’s scientific formulations to create high quality end products custom designed for THC and CBD precise dosing,” noted Timothy Shaw, COO of MariMed. “Conveniently located near our client’s cultivation facility in Las Vegas, we are confident they share MariMed’s passion for excellence and quality as they have developed their own ultra efficient extraction technologies and are one of the few companies that has been successfully producing and distributing medical cannabis in Nevada since it became legal. They have also proven they can produce the potency and purity of the extracts specified for our precision dosed products, which will help our brands maintain the quality and consistency for which we are known.”
“The partnership with MariMed, allows AMA to expand the breadth and depth of its product offering to dispensaries in the rapidly growing Nevada market,” stated Mark Zobrist, Managing Partner at AMA. “We are pleased to partner with MariMed to produce and distribute their very popular line of cannabis infused products that are raising the bar for ease of use, consistent dosage and predictable results. MariMed has a reputation for exact dosing delivered in unique, convenient packages for both medicinal and recreational uses. We believe they will be enthusiastically embraced in Las Vegas and throughout Nevada.”
About MariMed Inc.
MariMed Inc., collectively with its subsidiaries MariMed Advisors and various holdings, designs, develops, finances, and optimizes medical cannabis cultivation, production, and dispensary facilities as a management service. MariMed's team has developed or is in the process of developing state-of-the art regulatory-compliant facilities in DE, IL, NV, MD, MA and RI. These facilities are models of excellence in horticultural principals, cannabis production, product development, and dispensary operations. MariMed is on the forefront of precision dosed products for the treatment of specific medical conditions. It currently distributes its branded products in select states and is expanding licensing and distribution to numerous additional states encompassing thousands of dispensaries. MariMed Inc., is one of the 17 top-performing public cannabis companies in the U.S. tracked on the U.S. Marijuana Index, (www.marijuanaindex.com). For more info visit www.MarimedAdvisors.com
About Kalm Fusion
Kalm Fusion, a MariMed Inc., owned brand of all-natural cannabis products, is designed to make treatment a part of life that patients look forward to. Evoking “Kalm” as a lifestyle, the company aims to bring relief through enjoyable, reliable treatment and utmost respect to Mother Nature and body science. Kalm Fusion products are formulated with precision dosing for individual needs. Kalm Fusion products go through rigorous R & D and multiple layers of internal and third party laboratory testing to ensure consistency and precise dosing in product formulations. For more information on Kalm Fusion products, corporate social responsibility and licensing, visit www.KalmFusion.com
This release contains certain forward-looking statements and information relating to MariMed Inc., that is based on the beliefs of MariMed Inc. management, as well as assumptions made by and information currently available to the Company. Such statements reflect the current views of the Company with respect to future events including estimates and projections about its business based on certain assumptions of its management, including those described in this Release. These statements are not guarantees of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company's services and products, changes in the economic environment and changes in technology. Additional risk factors are included in the Company's public filings with the SEC. Should one or more of these underlying assumptions prove incorrect, actual results may vary materially from those described herein as "hoped," "anticipated," "believed," "planned, "estimated," "preparing," "potential," "expected" or words of a similar nature. The Company does not intend to update these forward-looking statements. None of the content of any of the websites of any other party referred to herein (even if a link is provided for your convenience) is incorporated into this release and the Company assumes no responsibility for any of such content.
Jon Levine, CFO, MariMed
Tyler Troup, Circadian Group
+1 (866) 950 8300
Julie Shepherd, Accentuate PR